NewcelX Ltd. Ordinary Shares
NCELStock
$3.91−81.31%52W
Market Cap$21.01M
P/E—
Div yield—
Beta0.91
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)62.14%
Price vs S&P 500 (4W)24.77%
VGM Score53.90
Market Capitalization$21.01M
Analyst Recommendations
Jan 2025
Feb 2025
Mar 2025
Apr 2025
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NCELNewcelX Ltd. Ordinary Shares | — | — | C | $3.91 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
NewcelX Ltd develops cell-based and small-molecule therapies for neurodegenerative and metabolic diseases using integrated stem-cell and neuroscience platforms. The company targets major unmet medical needs including ALS and Type 1 Diabetes through regenerative treatment approaches. Headquartered in Ness Ziona, Israel, NewcelX seeks to deliver scalable solutions to significant patient populations.